Status:
COMPLETED
Regulatory T-cells in Psoriasis Patients as Targets for Therapy
Lead Sponsor:
University of Aberdeen
Collaborating Sponsors:
NHS Grampian
Conditions:
Psoriasis
Eligibility:
All Genders
18-70 years
Brief Summary
The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-f...
Detailed Description
This is an observational study for the effect of different treatment options of psorisis on regulatory T-cells. Patients in whom a decision to treat with one of the following therapies (Dovobet, neoti...
Eligibility Criteria
Inclusion
- • Male and female patients in the age range from 18 to 70 who are diagnosed with moderate to severe psoriasis.
- Patients must be treatment free for at least 2 weeks for topical application and 4 weeks for systemic treatment of psoriasis.
- Women of child bearing potential must be on reliable contraception.
- Patients in whom a decision to treat with one of the following therapies has already been made based on normal clinical care:
- Dovobet
- Neotigason
- Narrow-band UVB
- Etanercept
- Adalimumab
- Infliximab
- 10 normal controls
Exclusion
- • Children below 18 years and patients over 70 years.
- Pregnant and lactating patients.
- Patients who are known to have immunosuppressive disease (e.g. HIV) or on any immunosuppressive therapy.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01233583
Start Date
June 1 2010
End Date
September 1 2013
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Burnside House
Aberdeen, United Kingdom, AB25 2ZR